Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


E-learning: Quarterly Focus on Genitourinary Cancer | RCC

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.

In this second episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Renal Cell Carcinoma from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications.

The expert panel consist of:

  • Prof. John Haanen, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam

  • Hans Westgeest, MD, medical oncologist, Amphia Ziekenhuis, Breda

  • Astrid van der Veldt, MD, PhD, medical oncologist, Erasmus MC, Rotterdam

Program:

Invited speaker: Kathleen Mahoney, MD, PhD, medical oncologist, Beth Israel Deaconess Medical Center, Boston

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma N Engl J Med 378, 2018

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Nature Medicine 24, 2018

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

E-learnings 04/03/2019

E-learning: Update on Renal cell carcinoma with prof. Camillo Porta

During a special Speaker Tour meeting prof. Camillo Porta visited the NKI-AVL to discuss challenges and best practices within the changing treatment landscape in (m)RCC.  ‘With the development of new therapeutic systemic options for the treatment of mRCC, including immunotherapy, novel TKIs and combination treatment, we find ourselves standing at the verge of a new era of therapeutic possibilities.  Our challenge is to find the best possible treatment algorithm for each (m)RCC patient.’ Topics that are discussed in this e-learning are: When are we ready for adjuvant therapy? What is the role of cytoreductive nephrectomy in mRCC? How to choose from the available options for first, second, and third line treatment? What may be the impact of immunotherapy and novel TKIs on the treatment algorithm? Chair and co-discussant: prof. J. Haanen, medical oncologist, NKI-AVL

Congress news 13/12/2018

EMUC 2018: Frail patients and the CARMENA trial

Dr. Umberto Capitanio, urologist at the IRCCS Ospedale San Raffaele in Italy and chief editor of the kidney cancer section of the UROONCO educational platform, talks about the EMUC 2018 discussion about frail patients. Furthermore he mentions the discussion about the Carmena trial in which nephrectomy plus adjuvant sunitinib is compared to sunitinib alone in patients with metastatic renal cell cancer.

Congress news 22/03/2018

ASCO GU 2018: Progression after IO combination regimens mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined the clinical outcome of patients with metastatic renal cell carcinoma progressing on frontline immune-oncology based combination regimens.

Congress news 22/03/2018

ASCO GU 2018: Renal Cell Carcinoma News Program

This year the ASCO Genitourinary Cancers Symposium took place in San Francisco from February 8th - 10th. In this Renal Cell Carcinoma News Program, we focus on the highlights for RCC at this congress. Moderator Catherine Hood and a panel of international experts discuss the following topics: Adjuvant systemic therapy Cabozantinib in the first line treatment of metastatic RCC The NIVOREN trial that investigates nivolumab in a ‘real world setting’ Combination treatments with VEGF and PD1/PD-L1 inhibition Advances in treatment for papillary RCC Speakers: Prof. Joaquim Bellmunt, MD, medical oncologist, Dana-Farber/Brigham and Women's Cancer Center, Boston Daniel George, MD, medical oncologist, Duke Cancer Center, Durham Jeanny Aragon-Ching, MD, medical oncologist, Inova Fairfax hospital, Fairfax Sumanta Pal, MD, medical oncologist, City of Hope Comprehensive Cancer Center, Duarte Moderator: Catherine Hood

Congress news 22/03/2018

ASCO GU 2018: Oligoprogressive mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined what the impact was of switching systemic treatment after radiosurgery for oligoprogressive, metastatic renal cell carcinoma.

Congress news 22/03/2018

ASCO GU 2017: RCC news

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. The final congress day was dedicated to renal cell carcinoma. A panel of American experts will bring you the day’s highlights, which include: circulating tumor DNA frontline systemic therapy (CABOSUN, IMmotion) TKI+immunotherapy active surveillance in localized and advanced disease imaging and biomarkers for the diagnosis and monitoring of RCC cryoablation adjuvant treatment for localized tumors (ASSURE, S-TRAC) hereditary renal cancer Speakers: Prof. Eric Jonasch MD, medical oncologist, University of Texas MD Anderson cancer center, Houston TX Sumanta Pal MD, medical oncologist, City of Hope, Duarte CA Prof. Mohamad Allaf MD, urologic oncologist, John Hopkins School of Medicine, Baltimore MD Moderator: Catherine Hood PhD The news program includes an interview with prof. Thomas Powles (Barts and the London School of Medicine, UK) on the results of the IMmotion trial and his expectations for the future of atezolizumab in RCC.

E-learnings 04/03/2019

E-learning: Update on Renal cell carcinoma with prof. Camillo Porta

During a special Speaker Tour meeting prof. Camillo Porta visited the NKI-AVL to discuss challenges and best practices within the changing treatment landscape in (m)RCC.  ‘With the development of new therapeutic systemic options for the treatment of mRCC, including immunotherapy, novel TKIs and combination treatment, we find ourselves standing at the verge of a new era of therapeutic possibilities.  Our challenge is to find the best possible treatment algorithm for each (m)RCC patient.’ Topics that are discussed in this e-learning are: When are we ready for adjuvant therapy? What is the role of cytoreductive nephrectomy in mRCC? How to choose from the available options for first, second, and third line treatment? What may be the impact of immunotherapy and novel TKIs on the treatment algorithm? Chair and co-discussant: prof. J. Haanen, medical oncologist, NKI-AVL

Meet the author 10/01/2019

Quarterly Focus on Hematology | CLL

Treating patients with chronic lymphocytic leukemia in an optimal fashion seems to become more complex every day. After all, our knowledge of the underlying biological complexity keeps on growing, creating new subgroups of patiets, and on top of that new potential drug combinations are constantly being developed and presented. In this program, a very international discussion panel will guide you through 2 highly relevant publications, helping you better understan the latest developments in the field of CLL. Guests Prof. Arnon Kater, MD, PhD Hematologist, Amsterdam UMC (AMC), The Netherlands Prof. Stephan Stilgenbauer, MD Hematologist, Saarland University, Homburg & Ulm University, Ulm, Germany Gert Jan Timmers, MD, PhD Hematologist, Amstelland Ziekenhuis, Amstelveen, The Netherlands Prof. Paolo Ghia, MD, PhD Internist, Università Vita-Salute San Raffaele, Milan, Italy Kostas Stamatopoulos, MD, PhD CERTH, Thessaloniki, Greece   Publications to be discussed Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study - Kater et al., JCO, december 2018 Cytogenetic Complexity in Chronic Lymphocytic Leukemia: Definitions, Assiciations and Clinical Impact - Baliakas et al, Blood, January 2019 About our "Quarterly Focus" format Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.